Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney function and Weight-Loss drug: a safety check

NCT ID NCT07429045

First seen Feb 25, 2026 · Last updated May 23, 2026 · Updated 11 times

Summary

This study looked at how a single dose of the experimental drug AMG 133 is processed in the body of people with normal kidney function compared to those with various levels of kidney problems. It involved 44 overweight adults. The goal was to gather safety and drug-level information, not to treat obesity directly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • AdvancedPharma CR LLC

    Miami, Florida, 33147-4040, United States

  • Floridian Clinical Research, LLC

    Miami Lakes, Florida, 33016, United States

  • Omega Research Group, LLC - Orlando

    Orlando, Florida, 32806-1133, United States

  • Orange County Research Center

    Lake Forest, California, 92630, United States

  • Orlando Clinical Research Center

    Orlando, Florida, 32809-3017, United States

Conditions

Explore the condition pages connected to this study.